These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36757568)

  • 21. Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.
    Bhadhuri A; Dröschel D; Guldimann M; Jetschgo C; Banhazi J; Schwenkglenks M; Sutherland CS
    BMC Health Serv Res; 2022 Jun; 22(1):837. PubMed ID: 35765055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
    Oh A; Tran DM; McDowell LC; Keyvani D; Barcelon JA; Merino O; Wilson L
    J Manag Care Spec Pharm; 2017 Jun; 23(6):653-664. PubMed ID: 28530525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.
    Capri S; Porta C; Delea TE
    Clin Ther; 2017 Mar; 39(3):567-580.e2. PubMed ID: 28189363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States.
    McCrea C; Johal S; Yang S; Doan J
    Exp Hematol Oncol; 2018; 7():4. PubMed ID: 29456880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China.
    Wang H; Wang Y; Li L; Zhou H; Lili S; Li L; Yike S; Aixia M
    Front Public Health; 2022; 10():954264. PubMed ID: 36159269
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan.
    Mo X; Moriwaki K; Morimoto K; Shimozuma K
    Clin Drug Investig; 2022 Jul; 42(7):599-609. PubMed ID: 35675029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
    Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
    Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan.
    Paly VF; Hikichi Y; Baker T; Itakura E; Chandran N; Harrison J
    J Med Econ; 2020 Dec; 23(12):1542-1552. PubMed ID: 33000994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma.
    Liu R; Qiu K; Wu J; Jiang Y; Wu P; Pang J
    Immunotherapy; 2022 Aug; 14(11):859-869. PubMed ID: 35754404
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies.
    Li S; Li J; Peng L; Li Y; Wan X
    Front Pharmacol; 2021; 12():718014. PubMed ID: 34566643
    [No Abstract]   [Full Text] [Related]  

  • 31. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.
    Wu B; Zhang Q; Sun J
    J Immunother Cancer; 2018 Nov; 6(1):124. PubMed ID: 30458884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
    Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
    N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India.
    Gupta D; Singh A; Gupta N; Mehra N; Bahuguna P; Aggarwal V; Krishnamurthy MN; Roy PS; Malhotra P; Gupta S; Kumar L; Kataki A; Prinja S
    JCO Glob Oncol; 2023 Feb; 9():e2200246. PubMed ID: 36795991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-line nivolumab plus ipilimumab or chemotherapy
    Cao X; Cai H; Li N; Zheng B; Zheng Z; Liu M
    Ther Adv Med Oncol; 2022; 14():17588359221122733. PubMed ID: 36147862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer.
    Hao X; Shen A; Wu B
    Front Pharmacol; 2021; 12():573852. PubMed ID: 34290602
    [No Abstract]   [Full Text] [Related]  

  • 36. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.
    Motzer RJ; McDermott DF; Escudier B; Burotto M; Choueiri TK; Hammers HJ; Barthélémy P; Plimack ER; Porta C; George S; Powles T; Donskov F; Gurney H; Kollmannsberger CK; Grimm MO; Barrios C; Tomita Y; Castellano D; Grünwald V; Rini BI; McHenry MB; Lee CW; McCarthy J; Ejzykowicz F; Tannir NM
    Cancer; 2022 Jun; 128(11):2085-2097. PubMed ID: 35383908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.
    Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Leung D; Saggi SS; Lee CW; McHenry MB; Motzer RJ
    Eur Urol; 2022 Mar; 81(3):266-271. PubMed ID: 34750035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
    Albiges L; Tannir NM; Burotto M; McDermott D; Plimack ER; Barthélémy P; Porta C; Powles T; Donskov F; George S; Kollmannsberger CK; Gurney H; Grimm MO; Tomita Y; Castellano D; Rini BI; Choueiri TK; Saggi SS; McHenry MB; Motzer RJ
    ESMO Open; 2020 Nov; 5(6):e001079. PubMed ID: 33246931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temporal trends of adverse events and costs of nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma.
    Geynisman DM; Du EX; Yang X; Sendhil SR; Tejo VD; Betts KA; Huo S
    Future Oncol; 2022 Mar; 18(10):1219-1234. PubMed ID: 34939424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer.
    Wan X; Zeng X; Peng L; Peng Y; Liu Q; Yi L; Luo X; Deng Q; Tan C
    Front Pharmacol; 2021; 12():580459. PubMed ID: 34512315
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.